Bias in the reporting of harms in clinical trials of second-generation antidepressants: The tip of the iceberg?

Serious adverse events are poorly reported in clinical trials of second-generation antidepressants. Moreover some key opinion leaders (eg. in France) deliberately failed to warn against them. The gross distortions of antidepressants' benefit:harm ratio in adolescents showed evidence that open science (ie access to de-identified individual patient data for re-analyses) is a mandatory prerequisite for a trustworthy science.